ClinicalTrials.gg
Active, not recruitingNCT04439227Updated Nov 18, 2026Results posted

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

A Phase 2 interventional study of Adavosertib in Advanced Lymphoma, Advanced Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by National Cancer Institute (NCI). Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 2 months after the study started (first participant enrolled Mar 2017, registered Jun 2020).
Updated Oct 6, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 60 studies in Hematologic Neoplasms by National Cancer Institute (NCI) — 12 open to participants now, 33 under way, none of them phase 3. Hematologic Neoplasms · National Cancer Institute (NCI).

Enrollment
33rd of 52
33 · median 38
Started
2017
with 2 others
Phase 2
31 of 60
1 open now
Primary completion
2020-05
later than 6 of 32 live
Registered
29th of 60
by date

Among the 60 studies in Hematologic Neoplasms by National Cancer Institute (NCI), this one is the 33rd largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2017, is one of 31 in phase 2, reaches primary completion later than 6 of the 32 other live ones, and was the 29th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

12 of the 60 studies in Hematologic Neoplasms by National Cancer Institute (NCI) are open now, in 2 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Hematologic Neoplasms by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

This phase II MATCH treatment trial identifiesay block the protein tyrosine kinase WEE1 the effects of AZD1775 in patients whose cancer has a genetic change called BRCA mutation. AZD1775 may block a protein called WEE1, which may be needed for growth of cancer cells that express BRCA mutations. Researchers hope to learn if AZD1775 will shrink this type of cancer or stop its growth.

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.

SECONDARY OBJECTIVES:

I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas/multiple myeloma.

II. To evaluate time until death or disease progression. III. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, ribonucleic acid (RNA), protein and imaging-based assessment platforms.

IV. To assess whether radiomic phenotypes obtained from pre-treatment imaging and changes from pre- through post-therapy imaging can predict objective response and progression free survival and to evaluate the association between pre-treatment radiomic phenotypes and targeted gene mutation patterns of tumor biopsy specimens.

OUTLINE:

Patients receive adavosertib (AZD1775) orally (PO) once daily (QD) on days 1-5 and 8-12 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months if less than 2 years from study entry, and then every 6 months for an additional year from study entry.

THE MATCH SCREENING TRIAL:

Please see NCT02465060 for information on the MATCH Screening Protocol and applicable documents.

03

Conditions studied

  • Advanced Lymphoma
  • Advanced Malignant Solid Neoplasm
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Refractory Lymphoma
  • Refractory Malignant Solid Neoplasm
  • Refractory Multiple Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol
  • Patients must have mutation in the BRCA1 or BRCA2 gene in the tumor, or another aberration, as determined via the MATCH Master Protocol. Patients with tumor carrying mutations defined as variants of uncertain significance will not qualify
  • Patients with ovarian cancer or negative, breast cancer must have received a PARP inhibitor as part of or as one of their
  • Patients must have an (ECG) within 8 weeks prior to treatment assignment and must have no abnormalities in rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, third degree heart block)
  • Patients receiving any medications or substances that are inhibitors or inducers of , or CYP3A4 substrates need to be reviewed by the study investigator. Continuation of such medications will be at the discretion of the study investigator. Concomitant use of aprepitant and fosaprepitant is prohibited
  • Patients have (HgB) >= 9 g/dL, which should be done =\< 4 weeks prior to registration to treatment step
  • Resting corrected using the Fridericia formula (QTcF) should be \< 450 msec/male and \< 470 msec/female (as calculated per institutional standards) obtained from electrocardiogram (ECG), prior to enrollment. If resting QTc interval using the Fridericia formula (QTcF) is > 450 msec/male and > 470 msec/female (as calculated per institutional standards), then 2 additional ECGs should be performed 2-5 minutes apart at study entry. In order to be eligible, the mean resting corrected QTc interval using the Fridericia formula (QTcF) should be \< 450 msec/male and \< 470 msec/female (as calculated per institutional standards)

Exclusion criteria

Exclusion Criteria:

  • Patients must not have known to AZD1775 or compounds of similar chemical or biologic composition
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Treatment (adavosertib)

    Patients receive adavosertib PO QD on days 1-5 and 8-12 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

    Drug: Adavosertib

Interventions

  • Given PO

    Also known as: AZD 1775, AZD-1775, AZD1775, MK 1775, MK-1775, MK1775

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of patients whose tumors have a complete or partial response to treatment among analyzable patients. Objective response is defined consistent with Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Details about how to define complete response and partial response can be found in the master protocol. 90% two-sided binomial exact confidence interval is calculated for ORR.

    Time frame: Tumor assessments occurred at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration

Secondary outcomes

  1. 6-month Progression-Free Survival (PFS)

    Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro- Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression. 6 month PFS rate was estimated using the Kaplan-Meier method, which can provide a point estimate for any specific time point.

    Time frame: Assessed at baseline, then every 3 cycles for the first 33 cycles, and every 4 cycles thereafter until disease progression, up to 3 years post registration, from which 6-month PFS rate is determined

  2. Progression-free Survival

    PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression.

    Time frame: Assessed at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration

07

Results

Posted Oct 6, 2026

Participant flow

Subprotocol Z1I was activated on March 13, 2017. Thirty-three patients were enrolled on EAY131-Z1I between March 24, 2017, and August 9, 2017.

Participant flow — Overall Study
MilestoneTreatment (Adavosertib)
Started33
Started protocol therapy33
Eligible and treated30
Completed0
Not completed33
Withdrew: Ineligible3
Withdrew: Adverse event4
Withdrew: Death1
Withdrew: Disease progression19
Withdrew: Withdrawal by subject5
Withdrew: Physician decision1

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR is defined as the percentage of patients whose tumors have a complete or partial response to treatment among analyzable patients. Objective response is defined consistent with Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Details about how to define complete response and partial response can be found in the master protocol. 90% two-sided binomial exact confidence interval is calculated for ORR.

Time frame:
Tumor assessments occurred at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsTreatment (Adavosertib)
Objective Response Rate (ORR)3.3 (0.2 to 14.9)
Secondary6-month Progression-Free Survival (PFS)

Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro- Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression. 6 month PFS rate was estimated using the Kaplan-Meier method, which can provide a point estimate for any specific time point.

Time frame:
Assessed at baseline, then every 3 cycles for the first 33 cycles, and every 4 cycles thereafter until disease progression, up to 3 years post registration, from which 6-month PFS rate is determined
Reported as:
Number · percentage of participants
6-month Progression-Free Survival (PFS)
percentage of participantsTreatment (Adavosertib)
6-month Progression-Free Survival (PFS)23.4 (10.7 to 36.2)
SecondaryProgression-free Survival

PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression.

Time frame:
Assessed at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration
Reported as:
Median · months
Progression-free Survival
monthsTreatment (Adavosertib)
Progression-free Survival2.0 (1.5 to 2.1)

Adverse events

Collected over Assessed every 21 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Adavosertib)27/33 (81.8%)18/33 (54.5%)26/33 (78.8%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventTreatment (Adavosertib)
Neutrophil count decreasedInvestigations7/33
FatigueGeneral disorders4/33
NauseaGastrointestinal disorders4/33
Platelet count decreasedInvestigations4/33
White blood cell decreasedInvestigations4/33
HyperglycemiaMetabolism and nutrition disorders4/33
AnemiaBlood and lymphatic system disorders3/33
VomitingGastrointestinal disorders3/33
HypophosphatemiaMetabolism and nutrition disorders3/33
DiarrheaGastrointestinal disorders2/33
Most frequent other events
Showing 10 of 43
Most frequent other events
EventTreatment (Adavosertib)
FatigueGeneral disorders17/33
DiarrheaGastrointestinal disorders15/33
NauseaGastrointestinal disorders13/33
AnemiaBlood and lymphatic system disorders12/33
Aspartate aminotransferase increasedInvestigations8/33
HypoalbuminemiaMetabolism and nutrition disorders8/33
VomitingGastrointestinal disorders7/33
Alkaline phosphatase increasedInvestigations7/33
White blood cell decreasedInvestigations7/33
HyperglycemiaMetabolism and nutrition disorders7/33

Baseline characteristics

Patients who were eligible and started protocol therapy were the analyzable patients

Age, Continuous
Age, Continuous(years)Treatment (Adavosertib)
Median61.5 (36 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Adavosertib)
Female19
Male11
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment (Adavosertib)
Hispanic or Latino2
Not Hispanic or Latino27
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Adavosertib)
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American4
White23
More than one race1
Unknown or Not Reported0
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in May 2020, 38 months.

Results were first posted in Oct 2026, 6 years 4 months after primary completion.

Of 114 non-industry phase 2 interventional studies under Hematologic Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 95. This study's 38 months is below that.

Counting every sponsor, half of 136 studies reached it within 57 months; a quarter within 40 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2020
First posted
Jun 19, 2020
StartActual
Mar 24, 2017
Primary completionActual
May 29, 2020
CompletionEst.
Dec 31, 2026
Results first posted
Oct 6, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 6, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedObjective response rateResponse Rate (ORR)Time frame: Up to 3 years → Tumor assessments occurred at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration
Oct 6, 2026
Documents
Oct 6, 2026
Publications
Results publication added: Kummar S, Song Z, Reiss KA, Ford JM, Chen L, Rolig AS, Zwiebel JA, Gore SD, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Gross J, Brunnquell D, Jackso… PubMed 42308463 ↗
Oct 6, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • Edited6-month progressionProgression-free survivalFree Survival (PFS) rateTime frame: From start of treatment on that step until determination of disease progression or death from any cause, censored at the date of last disease assessment for patients who have not progressed, assessed at 6 months → Assessed at baseline, then every 3 cycles for the first 33 cycles, and every 4 cycles thereafter until disease progression, up to 3 years post registration, from which 6-month PFS rate is determined
  • EditedProgression -free survival (PFS)SurvivalTime frame: From start of treatment on that step until determination of disease progression or death from any cause, censored at the date of last disease assessment for patients who have not progressed, assessed up to 3 years → Assessed at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration
Oct 6, 2026
Show all 3 updates
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 27, 2026
    Minor edits only
    + 4 other changes: verification date, conditions, references and data sharing statement
  3. Oct 6, 2026
    Results posted
    Documents Study protocol ↗ updated · Informed consent form ↗ posted
    Publications Results publication added: Kummar S, Song Z, Reiss KA, Ford JM, Chen L, Rolig AS, Zwiebel JA, Gore SD, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Gross J, Brunnquell D, Jackso… PubMed 42308463 ↗
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedObjective response rateResponse Rate (ORR)Time frame: Up to 3 years → Tumor assessments occurred at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration
    Secondary outcomes 2 edited
    What changed in the outcomes
    • Edited6-month progressionProgression-free survivalFree Survival (PFS) rateTime frame: From start of treatment on that step until determination of disease progression or death from any cause, censored at the date of last disease assessment for patients who have not progressed, assessed at 6 months → Assessed at baseline, then every 3 cycles for the first 33 cycles, and every 4 cycles thereafter until disease progression, up to 3 years post registration, from which 6-month PFS rate is determined
    • EditedProgression -free survival (PFS)SurvivalTime frame: From start of treatment on that step until determination of disease progression or death from any cause, censored at the date of last disease assessment for patients who have not progressed, assessed up to 3 years → Assessed at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration
    + 5 other changes: verification date, description, conditions, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04439227
Responsible party
Sponsor
First posted
Jun 19, 2020
Start date
Mar 24, 2017
Primary completion
May 29, 2020
Completion
Dec 31, 2026 (estimated)
Results posted
Oct 6, 2026
Last update
Nov 18, 2026

Study contacts

Shivaani Kummar
principal investigator · ECOG-ACRIN Cancer Research Group

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adavosertib

Start the discussion